Shows
BioInsightsBioInsights talks to Marco Benitez CEO of Rook "How Data and Wearables Are Changing Everything"Summary
In this conversation, Marcelo Aller and Marco Benitez discuss the intersection of health technology and wearables, focusing on how data can empower individuals on their health journeys. Marco shares his background as a biomedical engineer and entrepreneur, detailing the evolution of wearables and their role in fitness and health. The discussion emphasizes the importance of preventive health, the integration of wearables into gym operations, and the future of health data science. Marco highlights the need for personalized health experiences and the significance of building relationships within the startup ecosystem.
Takeaways
1. Wearables are...2025-03-1353 minBioInsightsBioInsights talks to Andrew Menter the CEO of Physmodo about tech and assessmentSummary
In this conversation, Marcelo Aller interviews the CEO of Physmodo, Andrew Menter, about the company's innovative optical technology for health and fitness. They explore the inspiration behind the technology, the challenges faced in development, and the importance of data in enhancing trainer-client interactions. The discussion also covers privacy compliance, the role of continuous data in health monitoring, and future market opportunities for Physmodo. Andrew shares insights on user experience, validation of movement assessments, and funding challenges in the current market landscape.
Takeaways
Injuries can often be prevented with proper as...2025-02-241h 04BioInsightsBioInsights talks with Steven Webster, the CEO of AsenseiToday, we will discuss exciting technologies and the visionaries behind them. We are honored to have Steven Webster, the Founder and CEO of Asensei. His company is changing personal training with advanced sensors and artificial intelligence. Steven has a strong background in user experience design and has led many successful teams and startups. He brings valuable knowledge to our discussion. Let’s explore innovative fitness and the future of personalized coaching.
Keywords
Asensei, Steven Webster, connected fitness, industrial athletes, health technology, coaching intelligence, movement recognition, AI in fitness, privacy in...2025-02-0253 minBioInsightsBioInsights talk with Bob Esquerre: The Big Four Fitness Challenges: Navigating Growth in a Competitive Market.Summary of this conversation:
Marcelo Aller and Bob Esquerre discuss the evolving landscape of the health and fitness industry, focusing on the challenges and opportunities ahead in 2025. They explore the importance of understanding the value proposition for consumers, the need for a customer-centric experience, and the role of fitness professionals in adapting to these changes. The discussion also touches on the significance of mentorship, economic shifts' impact, and AI's integration in fitness. Ultimately, they emphasize the necessity of training movement rather than just muscle and the importance of creating a supportive environment for all clients.
...2025-01-2651 minBioInsightsBioInsights Talks with Peter from Ventriject Health and Habit TechnologyIn this episode, Marcelo Aller interviews Peter from Ventreject, focusing on the innovative technology of seismocardiography and its application in measuring VO2 max. They discuss the science behind this technology, its business model, and the significance of VO2 max as a health indicator. The conversation also explores topics such as building healthy habits, the future of health technology, and the role of data in fitness and health management.
Takeaways
Ventreject aims to revolutionize VO2 max measurement.
Seismocardiography provides accurate health metrics quickly.
VO2 max is a critical indicator of overall health.
Preventive healthcare can reduce long-term...2024-12-261h 06BioInsightsBioInsights talks to Coach Bewley from Critical Reload and how biometric data impacts nutritionSummary
In this episode of Biolinsights, Marcelo Aller interviews Coach Michael Bewley, a seasoned expert in sports nutrition and strength conditioning. They discuss the evolution of strength and conditioning in Division 1 athletics over the past two decades, the impact of technology on athletic performance, and the challenges of educating athletes about nutrition. Bewley shares insights on the misconceptions surrounding athletic nutrition, the importance of building relationships with athletes, and the development of his nutritional supplement, Critical Reload. The conversation emphasizes the need for a balanced approach to nutrition and the significance of tracking athletes' nutritional habits to...2024-12-1754 minBioInsightsBioInsights with Daniel Crumback- Metabolic Training and testing with KORRThis podcast discusses the science of physiological data and how it relates to your health, happiness, and performance. Welcome to our podcast! We’re excited to introduce Daniel Crumback, an expert in physiological testing and metabolic health. As the Director of Sales for Europe at KORR Medical Technologies and a member of their Metabolic Science Advisory Board, Daniel brings 25 years of experience in the field.
With metabolic analysis and physiotherapy expertise, Daniel has mentored over 1,000 individuals in exercise prescription and respiratory training. He has also lectured at the University of Chichester and served as a Phy...2024-12-031h 00BioInsightsBioInsights Talk with Scot Damman of MovefactorXSummary
In this conversation, Marcelo Aller and Scott Gaman discuss the intersection of physiological data, health, and performance. They explore how movement sensors can enhance training and recovery for both athletes and the general population, emphasizing the importance of rate of force development and the need to challenge traditional methodologies in strength and conditioning. The discussion also touches on the future of movement technology, the role of data in coaching, and entrepreneurial insights in the health tech space.
Takeaways
Physiological data is crucial for understanding health and performance.
Mov...2024-11-2639 min
BioInsights"BioInsights - Data-Driven Athletics: Revolutionizing Training for Optimal Performance with Don Moxley."In this engaging conversation, Marcelo Aller and Don Moxley explore the evolution of the strength and conditioning industry, discussing the staleness in current practices and the need for innovation. They delve into the impact of technology on fitness, the future of conditioning facilities, and how the COVID-19 pandemic has reshaped training methodologies. The discussion emphasizes the importance of data, individualization in training, and the necessity for the fitness industry to adapt to meet the needs of a broader population. In this conversation, Don Moxley and Marcelo Aller delve into the intricacies of athletic training, emphasizing the importance of data-driven...2024-11-121h 01
The BioInsights PodcastPreparing for tomorrow’s cell and gene therapies today: lessons from 30 years in the fieldFor the first time in history, cell and gene therapy products are reaching the market in waves rather than in one’s and two’s, creating unprecedented challenges for pharma/biotech and healthcare sector stakeholders alike. David McCall, Senior Editor, BioInsights, speaks to Eric Faulkner, President and Chief Strategist, Passage Health Associates, about the chequered history of market access in the advanced therapies field, and what lessons can be taken forward to ensure a successful and sustainable commercial future for the sector. 2024-09-0625 minThe BioInsights PodcastInsights into advanced therapies in the context of evolving funding and M&A environmentsDavid McCall, Senior Editor, BioInsights, spoke to Lee Brown, Healthcare Sector Global Team Leader, Third Bridge Group, on Tuesday, February 6, 2024 to gain his insights into the fast-moving market landscape of advanced therapies. The discussion outlines key recent news and strategic moves from prominent pharma and biotech companies in the field, as well as the prospects for specific technologies such as CRISPR-based genome editing and next-generation CAR-T therapies.2024-06-1422 minThe BioInsights PodcastBuilding with the patient in mind: designing a state-of-the-art facility for viral vector manufacturingThe cell and gene therapy space poses a number of unique challenges when it comes to facility design. In this episode, Róisin McGuigan, Editor, BioInsights, speaks to Yposkesi’s Louis-Marie De Montgrand and Morad El Gueddari to discuss the key considerations for designing an advanced therapy manufacturing facility that can meet the needs of future commercial demand.To read this interview and access lots more content, visit the Cell and Gene Therapy Insights website.2023-10-1028 minThe BioInsights PodcastCan AAV continue to deliver the promise of gene therapy?In this episode, Charlotte Barker, Editor, BioInsights, will be discussing the future of AAV-based gene therapy manufacturing with Elie Hanania, VP of Process Development Viral Vector Technologies at Avid Bioservices, and Ratish Krishnan, Senior Strategy Consultant at Merck Life Sciences. 2023-09-1321 minThe BioInsights PodcastExpanding the potential of in vivo cell therapy with tLNP-RNAs (targeted lipid nanoparticle-RNA)The application of lipid nanoparticles (LNPs) as a non- viral delivery system for advanced therapies, in conjunction with RNA-based medicines, is set to revolutionize the field. In this episode, David McCall, Senior Editor, BioInsights, speaks to Adrian Bot, Chief Scientific Officer and Executive Vice President of R&D, Capstan Therapeutics, about the potential of these tools to drive the burgeoning in vivo cell therapy space in particular, and the broader gene medicine field in general.2023-08-3020 minThe BioInsights PodcastInvesting long-term in the cell & gene therapies of the futureDavid McCall, Senior Editor, BioInsights, speaks to Geeta Vemuri, Founder and Managing Partner, Agent Capital, about her VC company's portfolio of advanced therapy investments, and the keys to obtaining funding in a difficult environment. (From an interview conducted on February 22nd, 2023).2023-08-2215 minThe BioInsights PodcastHappy medium: considerations in scaling cell culture media strategiesWhile attractive from an initial cost perspective, performing early development in a cell culture substrate that does not match a therapy’s final manufacturing platform can have critical implications on development timelines. In this podcast, Charlotte Barker, Editor, BioInsights, speaks to Dalip Sethi, Director of Scientific Affairs, Terumo BCT, about best practices for scaling up cell culture substrate.2023-08-1619 minThe BioInsights PodcastModernizing cell therapy manufacturing to reduce vein-to-vein timesCharlotte Barker (Editor, BioInsights) speaks with Curate Biosciences’ CEO David Backer and CTO Tony Ward about the need for CAR-T cell therapy manufacturing to evolve, and how a new cell separation technique could boost efficiency.2023-07-2623 minThe BioInsights PodcastNavigating the complexities of biodistribution, transgene expression & vector shedding in gene therapy developmentIn this episode Róisin McGuigan (Editor, BioInsights) speaks to Paul Byrne (Senior Director, Genomics, ProtaGene) about the evolution of the gene therapy field, with a specific focus on the complexities posed by biodistribution, vector shedding, and transgene expression in gene therapy development.2023-06-0931 minThe BioInsights PodcastMaximizing Efficiency and Flexibility in Viral Vector Manufacturing Scale-upFour viral vector experts from diverse groups within Pall Corporation’s gene therapy manufacturing organization – Denis Kole, Jon Petrone, Marc Bisschops and Nathan Hazi – join BioInsights to share insights in hot topics for the field, including optimizing upstream process yield and titer, full/empty/partially full capsid separation, and platform process development.2023-03-0237 minThe BioInsights PodcastDe-risk & accelerate the drug development process for gene therapyIn today’s challenging financial environment, it is more important than ever to get key biotech business decisions right first time. One of the most important and topical of these is the choice of CDMO partner. Dr Kim Watanabe, General Manager and Site Head for Patheon Translational Services, a part of the Thermo Fisher Scientific pharma services contract development and manufacturing organizational arm, joins BioInsights to share her advice and insights into optimizing outsourcing strategy.2022-09-2911 min
The BioInsights PodcastPartnering in life sciences: what is the ‘secret sauce’ for success? PART 2Welcome to a 2-part series in which we identify and distill some key learnings for partnering success in today's life sciences sector.Perhaps one of the most valuable take-aways from the COVID-19 pandemic response is the sheer scale of what may be achieved through effective collaboration. Over the next three episodes, we'll talk to a range of different stakeholders from across BioInsights' fields of focus, asking them to pass on their tips for what works and what doesn't in this crucial aspect. Abi Pinchbeck, Assistant Editor, Immuno-oncology Insights, speaks t...2022-07-2519 minThe BioInsights PodcastPrecisely for CGT: automating aseptic filling for lowest volumesIn this Episode, Roisin McGuigan, Editor at BioInsights, speaks to Dr Barbara Fisher, Process Consultant at Single Use Support about automating aseptic filling for lowest volumes. Barbara works with both established pharmaceutical manufacturers and start-up companies, and has in-depth expedience in low bioburden and aseptic GMP manufacturing from downstream processing to fill and finish. To read this interview and access lots more content, visit the Cell and Gene Therapy Insights website.2022-05-1015 min
BioInsights Publishing ArchivePrecisely for CGT: automating aseptic filling for lowest volumesPrecisely for CGT: automating aseptic filling for lowest volumes by BioInsights Publishing2022-04-1115 min
BioInsights Publishing ArchivePrecisely for CGT: automating aseptic filling for lowest volumesPrecisely for CGT: automating aseptic filling for lowest volumes by BioInsights Publishing2022-04-0515 min
BioInsights Publishing ArchiveWhat are the most important factors to consider when looking to make significant cost savings?What are the most important factors to consider when looking to make significant cost savings? by BioInsights Publishing2022-04-0502 min
BioInsights Publishing ArchiveWhat are the biggest hurdles that needs to be overcome to speed up standardization and scale-up?What are the biggest hurdles that needs to be overcome to speed up standardization and scale-up? by BioInsights Publishing2022-04-0503 min
BioInsights Publishing ArchiveWhat specific trends are you seeing currently in the selection of primary packaging?What specific trends are you seeing currently in the selection of primary packaging? by BioInsights Publishing2022-04-0504 min
BioInsights Publishing ArchiveWhat are your top recommendations for manufacturers who are transferring from manual to automated?What are your top recommendations for manufacturers who are transferring from manual to automated? by BioInsights Publishing2022-04-0501 min
BioInsights Publishing ArchiveWhat are the key challenges when using single-use bags in small volume manufacturing?What are the key challenges when using single-use bags in small volume manufacturing? by BioInsights Publishing2022-04-0503 min
BioInsights Publishing ArchiveCan you detail your experience with Ilaria Scarfone implementing the MycoSEQ analytics?Can you detail your experience with Ilaria Scarfone implementing the MycoSEQ analytics? by BioInsights Publishing2022-03-0404 min
BioInsights Publishing ArchiveKey factors to consider for successful cell therapy manufacturing: a case studyKey factors to consider for successful cell therapy manufacturing: a case study by BioInsights Publishing2022-03-0237 min
BioInsights Publishing ArchiveCan you tell us a little bit more about what you do at the Meyer Children's Hospital?Can you tell us a little bit more about what you do at the Meyer Children's Hospital? by BioInsights Publishing2022-03-0210 min
BioInsights Publishing ArchiveWhat are the QC or analytical tests in your process to ensure the safety and quality of product?What are the QC or analytical tests in your process to ensure the safety and quality of product? by BioInsights Publishing2022-03-0203 min
BioInsights Publishing ArchiveWhat are the challenges you have identified and what are we working on at Thermo Fisher Scientific?What are the challenges you have identified and what are we working on at Thermo Fisher Scientific? by BioInsights Publishing2022-03-0206 min
BioInsights Publishing Archiveduplicated q 3duplicated q 3 by BioInsights Publishing2022-03-0206 min
BioInsights Publishing ArchiveAre there any other features that you think will be critical in the future?Are there any other features that you think will be critical in the future? by BioInsights Publishing2022-03-0209 min
BioInsights Publishing ArchiveAre there any other thoughts that we haven't touched upon?Are there any other thoughts that we haven't touched upon? by BioInsights Publishing2022-03-0203 min
BioInsights Publishing ArchiveResidual DNA testing in viral vector manufacture: exploring the challenges and solutionsResidual DNA testing in viral vector manufacture: exploring the challenges and solutions by BioInsights Publishing2022-02-1815 min
BioInsights Publishing ArchiveCould you give a brief introduction and background on the residual DNA?Could you give a brief introduction and background on the residual DNA? by BioInsights Publishing2022-02-1803 min
BioInsights Publishing ArchiveHow does the development validation study help ensure the quality of the kits?How does the development validation study help ensure the quality of the kits? by BioInsights Publishing2022-02-1803 min
BioInsights Publishing ArchiveHow do we help simplify the process of measuring vector DNA?How do we help simplify the process of measuring vector DNA? by BioInsights Publishing2022-02-1802 min
BioInsights Publishing ArchiveDo you have any suggestions on how to address copy number versus mass concerns?Do you have any suggestions on how to address copy number versus mass concerns? by BioInsights Publishing2022-02-1801 min
BioInsights Publishing ArchiveTherapeutic potential of extracellular vesiclesTherapeutic potential of extracellular vesicles by BioInsights Publishing2022-01-2131 min
BioInsights Publishing ArchiveThis modality is showing strong growth currently- what are the specific applications driving this?This modality is showing strong growth currently- what are the specific applications driving this? by BioInsights Publishing2022-01-2102 min
BioInsights Publishing ArchiveWhat are extracellular vesicles, and how they used in advanced therapies?What are extracellular vesicles, and how they used in advanced therapies? by BioInsights Publishing2022-01-2102 min
BioInsights Publishing ArchiveWhat is best practise in working with EVs across the various applications?What is best practise in working with EVs across the various applications? by BioInsights Publishing2022-01-2105 min
BioInsights Publishing ArchiveWhat are some of the key considerations and challenges in transitioning from MSCs to EVs?What are some of the key considerations and challenges in transitioning from MSCs to EVs? by BioInsights Publishing2022-01-2105 min
BioInsights Publishing ArchiveWhat are your expectations for the further development of the field?What are your expectations for the further development of the field? by BioInsights Publishing2022-01-2106 min
BioInsights Publishing ArchiveWhat have been the key innovations in technologies to drive advances in EV production?What have been the key innovations in technologies to drive advances in EV production? by BioInsights Publishing2022-01-2108 min
BioInsights Publishing ArchiveWhat was the vision for founding CERo?What was the vision for founding CERo? by BioInsights Publishing2021-11-2501 min
BioInsights Publishing ArchiveWhat's unique Cero's platform and approach?What's unique Cero's platform and approach? by BioInsights Publishing2021-11-2504 min
BioInsights Publishing ArchiveTell us more about your background and the main reasons why you joined CERo?Tell us more about your background and the main reasons why you joined CERo? by BioInsights Publishing2021-11-2504 min
BioInsights Publishing ArchiveIn what other ways are CERo's product candidates differentiated from other cell therapy modalities?In what other ways are CERo's product candidates differentiated from other cell therapy modalities? by BioInsights Publishing2021-11-2502 min
BioInsights Publishing ArchiveWhat key learnings and experience do you bring with you to your current roles?What key learnings and experience do you bring with you to your current roles? by BioInsights Publishing2021-11-2506 min
BioInsights Publishing ArchiveWhat are the chief considerations the integration of engineered cells with targeted therapies?What are the chief considerations the integration of engineered cells with targeted therapies? by BioInsights Publishing2021-11-2502 min
BioInsights Publishing ArchiveCan you go into more depth on CERo' harnessing of synthetic biology and bioinformatics?Can you go into more depth on CERo' harnessing of synthetic biology and bioinformatics? by BioInsights Publishing2021-11-2503 min
BioInsights Publishing ArchiveCan you tell us about the manufacturing model and your plans in that regard?Can you tell us about the manufacturing model and your plans in that regard? by BioInsights Publishing2021-11-2502 min
BioInsights Publishing ArchiveWhat are your ongoing preclinical development plans?What are your ongoing preclinical development plans? by BioInsights Publishing2021-11-2500 min
BioInsights Publishing ArchiveCan you tell us more about the molecules or treatments that could be combined with CER-Ts?Can you tell us more about the molecules or treatments that could be combined with CER-Ts? by BioInsights Publishing2021-11-2501 min
BioInsights Publishing ArchiveNew-generation T cell immunotherapy at the intersection of adaptive and innate immunityNew-generation T cell immunotherapy at the intersection of adaptive and innate immunity by BioInsights Publishing2021-11-2430 min
BioInsights Publishing ArchiveHow are specialist CDMO such as Vigene helping to address the safety of viral vectors?How are specialist CDMO such as Vigene helping to address the safety of viral vectors? by BioInsights Publishing2021-11-2402 min
BioInsights Publishing ArchiveWhat is the latest progress in enabling viral vector intensification?What is the latest progress in enabling viral vector intensification? by BioInsights Publishing2021-11-2402 min
BioInsights Publishing ArchiveWhat is your advice to those struggling with the requirement for earlier process decision making?What is your advice to those struggling with the requirement for earlier process decision making? by BioInsights Publishing2021-11-2405 min
BioInsights Publishing ArchiveHow does Charles River intend to address plasmid supply issues?How does Charles River intend to address plasmid supply issues? by BioInsights Publishing2021-11-2403 min
BioInsights Publishing ArchiveHow do regulatory and scientific requirements for plasmid differ for different products?How do regulatory and scientific requirements for plasmid differ for different products? by BioInsights Publishing2021-11-2410 min
BioInsights Publishing ArchiveWhat lessons can be learned from the COVID-19 pandemic?What lessons can be learned from the COVID-19 pandemic? by BioInsights Publishing2021-11-2403 min
BioInsights Publishing ArchiveCan you give us an overview of regulatory standards for viral clearance in gene therapy manufacture?Can you give us an overview of regulatory standards for viral clearance in gene therapy manufacture? by BioInsights Publishing2021-11-2404 min
BioInsights Publishing ArchiveWhat are the key advances in available assays and analytical tools?What are the key advances in available assays and analytical tools? by BioInsights Publishing2021-11-2404 min
BioInsights Publishing ArchiveWhat advice can you give developers preparing for a stringent regulatory environment?What advice can you give developers preparing for a stringent regulatory environment? by BioInsights Publishing2021-11-2404 min
BioInsights Publishing ArchiveWhat benefits does the collaboration between the 3 companies provide?What benefits does the collaboration between the 3 companies provide? by BioInsights Publishing2021-11-2404 min
BioInsights Publishing ArchiveHow are specialist CDMOs helping to address the safety of viral vector-based gene therapy?How are specialist CDMOs helping to address the safety of viral vector-based gene therapy? by BioInsights Publishing2021-11-2202 min
BioInsights Publishing ArchiveWhat is the latest progress in enabling viral vector process intensification?What is the latest progress in enabling viral vector process intensification? by BioInsights Publishing2021-11-2202 min
BioInsights Publishing ArchiveWhat is your advice to those struggling with the requirement for earlier process decision makingWhat is your advice to those struggling with the requirement for earlier process decision making by BioInsights Publishing2021-11-2202 min
BioInsights Publishing ArchiveCR Q04CR Q04 by BioInsights Publishing2021-11-2205 min
BioInsights Publishing ArchiveSufficient supply of hight-quality plasmid has been identified as a key potential bottleneck.Sufficient supply of hight-quality plasmid has been identified as a key potential bottleneck. by BioInsights Publishing2021-11-2213 min
BioInsights Publishing ArchiveCR Q06CR Q06 by BioInsights Publishing2021-11-2203 min
BioInsights Publishing ArchiveCan you give an overview of current regulatory standards or guidance for viral clearance?Can you give an overview of current regulatory standards or guidance for viral clearance? by BioInsights Publishing2021-11-2209 min
BioInsights Publishing ArchiveCR Q08CR Q08 by BioInsights Publishing2021-11-2204 min
BioInsights Publishing ArchiveKey topics in advanced therapy manufacturing: quality, safety, and supplyKey topics in advanced therapy manufacturing: quality, safety, and supply by BioInsights Publishing2021-11-2244 min
BioInsights Publishing ArchiveCR Q09CR Q09 by BioInsights Publishing2021-11-2204 min
BioInsights Publishing ArchiveHow can we make vector bioprocessing faster and more cost-effectiveHow can we make vector bioprocessing faster and more cost-effective by BioInsights Publishing2021-10-0703 min
BioInsights Publishing ArchiveWhere are the key throughput-related issues for vector manufacturing assays/analytical tools?Where are the key throughput-related issues for vector manufacturing assays/analytical tools? by BioInsights Publishing2021-10-0705 min
BioInsights Publishing ArchiveWhat tools are available for measuring the impact of various AAV vector engineering methods?What tools are available for measuring the impact of various AAV vector engineering methods? by BioInsights Publishing2021-10-0707 min
BioInsights Publishing ArchiveCan you provide an overview of Repligen solutions for therapeutic product quality attributes?Can you provide an overview of Repligen solutions for therapeutic product quality attributes? by BioInsights Publishing2021-10-0709 min
BioInsights Publishing ArchiveHow to drive further improvements in AAV vector process analytics?How to drive further improvements in AAV vector process analytics? by BioInsights Publishing2021-10-0706 min
BioInsights Publishing ArchiveAdvancing real-time monitoring of AAV vector processesAdvancing real-time monitoring of AAV vector processes by BioInsights Publishing2021-10-0740 min
BioInsights Publishing ArchiveHow is Repligen driving innovation of in-line process analytics?How is Repligen driving innovation of in-line process analytics? by BioInsights Publishing2021-10-0707 min
BioInsights Publishing ArchiveImproving AAV vector manufacture: a question of scaleImproving AAV vector manufacture: a question of scale by BioInsights Publishing2021-04-2324 min
BioInsights Publishing ArchiveWhat are the pros and cons of transient transfection versus stable producer cell line?What are the pros and cons of transient transfection versus stable producer cell line? by BioInsights Publishing2021-04-2304 min
BioInsights Publishing ArchiveWhat are the chief drivers for improving AAV vector manufacturing?What are the chief drivers for improving AAV vector manufacturing? by BioInsights Publishing2021-04-2302 min
BioInsights Publishing ArchiveWhat are the chief considerations for upstream bioprocess development?What are the chief considerations for upstream bioprocess development? by BioInsights Publishing2021-04-2303 min
BioInsights Publishing ArchiveWhat are the capabilities and advantages of the latest stirred tank bioreactors?What are the capabilities and advantages of the latest stirred tank bioreactors? by BioInsights Publishing2021-04-2302 min
BioInsights Publishing ArchiveCan you tell us about your own experiences in scaling-up into a stirred tank bioreactor?Can you tell us about your own experiences in scaling-up into a stirred tank bioreactor? by BioInsights Publishing2021-04-2303 min
BioInsights Publishing ArchiveTell us about your downstream bioprocessing experience with tangential flow filtration steps?Tell us about your downstream bioprocessing experience with tangential flow filtration steps? by BioInsights Publishing2021-04-2301 min
BioInsights Publishing ArchiveWhat downstream bioprocess technologies were used in the work with Cevec?What downstream bioprocess technologies were used in the work with Cevec? by BioInsights Publishing2021-04-2303 min
BioInsights Publishing ArchiveWhat are the key benefits in having a technology partner in vector bioprocess scale-up?What are the key benefits in having a technology partner in vector bioprocess scale-up? by BioInsights Publishing2021-04-2302 min
BioInsights Publishing ArchiveWhat are the do's and don'ts in tech transfer on the downstream side?What are the do's and don'ts in tech transfer on the downstream side? by BioInsights Publishing2021-04-2302 min
BioInsights Publishing ArchiveOn my bookshelf...On my bookshelf... by BioInsights Publishing2021-03-1515 min
BioInsights Publishing ArchiveCan you firstly introduce us to yourself and to Mission Bio?Can you firstly introduce us to yourself and to Mission Bio? by BioInsights Publishing2021-02-2303 min
BioInsights Publishing ArchiveWhy the recent move into cell and gene therapy? What can single-cell sequencing bring to this field?Why the recent move into cell and gene therapy? What can single-cell sequencing bring to this field? by BioInsights Publishing2021-02-2306 min